Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BMO Capital Maintains Outperform on Emera, Lowers Price Target to C$63

BMO Capital Maintains Outperform on Emera, Lowers Price Target to C$63

BMO Capital analyst Ben Pham maintains Emera (TSX:EMA) with a Outperform and lowers the price target from C$66 to C$63.

byBenzinga Newsdesk

October 20, 2022

1 minute read

BMO Capital analyst Ben Pham maintains Emera (TSX:EMA) with a Outperform and lowers the price target from C$66 to C$63.

Morgan Stanley Downgrades Outset Medical to Equal-Weight, Lowers Price Target to $20

By Benzinga Newsdesk

July 14, 6:27 AM

Morgan Stanley analyst Drew Ranieri downgrades Outset Medical (NASDAQ:OM) from Overweight to Equal-Weight and lowers the price target from $48 to $20.

GameStop Layoffs Begin Ahead Of Q3 Earnings: What Investors Need To Know

By AJ Fabino

December 6, 12:17 PM

GameStop Corp (NYSE: GME) is stepping back from its aggressive push into Web3/Cryprocurrency.

GME

Here’s How Much $1000 Invested In Mettler-Toledo Intl 20 Years Ago Would Be Worth Today

By Benzinga Insights

July 25, 11:00 AM

Mettler-Toledo Intl (NYSE:MTD) has outperformed the market over the past 20 years by 12.1% on an annualized basis…

MTD

News

What’s Going On With Marker Therapeutics (MRKR) Stock

By Henry Khederian

July 11, 10:03 AM

Marker Therapeutics, Inc. (NASDAQ: MRKR) shares are trading higher by 3.0% to $5.50 Tuesday morning.

MRKR

BMO Capital Maintains Outperform on Emera, Lowers Price Target to C$63

Related Posts

Morgan Stanley Downgrades Outset Medical to Equal-Weight, Lowers Price Target to $20

GameStop Layoffs Begin Ahead Of Q3 Earnings: What Investors Need To Know

Here’s How Much $1000 Invested In Mettler-Toledo Intl 20 Years Ago Would Be Worth Today

What’s Going On With Marker Therapeutics (MRKR) Stock